Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2020 Results - Earnings Call Transcript

SA Transcripts
153.96K Followers

Q4: 2021-03-04 Earnings Summary

EPS of -$6.20 misses by $1.06
 | Revenue of $5.70M (1,021.65% Y/Y) beats by $3.01M

Syros Pharmaceuticals, Inc. (OTC:SYRS) Q4 2020 Earnings Conference Call March 4, 2021 8:30 AM ET

Company Participants

Naomi Aoki - Vice President, Corporate Communications and Investor Relations
Nancy Simonian - Our Chief Executive Officer
David Roth - Chief Medical Officer
Joe Ferra - Chief Financial Officer

Conference Call Participants

Phil Nadeau - Cowen
Ted Tenthoff - Piper Sandler
Jason Butler - JMP Securities
Mark Breidenbach - Oppenheimer
Zegbeh Jallah - ROTH Capital
Matthew Cross - Alliance Global

Operator

Good morning and welcome to Syros Pharmaceuticals Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on Investors & Media section of Syros' website at www.syros.com. Please be advised that today's call is being recorded. Following the formal remarks, we will open the call up for your questions.

At this time, I'd like to turn the call over to Naomi Aoki, Vice President of Corporate Communications and Investor Relations at Syros.

Naomi Aoki

Thank you. This morning we issued a press release with our fourth quarter and full year 2020 financial results, along with anticipated future milestones and recent accomplishments. This release is available on the Investors & Media section of Syros's website at www.syros.com.

We will begin the call with prepared remarks by Dr. Nancy Simonian. Our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; and Joe Ferra, our Chief Financial Officer. We will then open the call for question. Dr. Eric Olson, our Chief Scientific Officer; and Dr. Jeremy Springhorn, our Chief Business Officer are also on the call and will be available for Q&A.

Before we begin, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially

Recommended For You

About SYRS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on SYRS